Gemigliptin (tartrate hydrate)

Gemigliptin (LC15-0444) tartrate hydrate is a selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate hydrate exhibits potent anti-glycation properties. Gemigliptin tartrate hydrate can be used for the research of advanced glycation end products (AGE) -related diabetic complications[1][2].

Product Specifications

CAS Number

[1375415-82-9]

Product Name Alternative

LC15-0444 (tartrate hydrate)

UNSPSC

12352005

Target

Dipeptidyl Peptidase

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Purity

99.83

Smiles

OC([C@H](O)[C@@H](O)C(O)=O)=O.O=C1N(C[C@@H](N)CC(N2CCC3=C(C(F)(F)F)N=C(C(F)(F)F)N=C3C2)=O)CC(F)(F)CC1.O.[1.5]

Molecular Formula

C18H19F8N5O2.C4H6O6.3/2H2O

Molecular Weight

666.49

References & Citations

[1]Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102.|[2]Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.